CDC Releases 2022 Hepatitis Surveillance Report and 2024 National Progress Report

Apr 04, 2024

CDC released the 2022 Viral Hepatitis Surveillance Report and 2024 Viral Hepatitis National Progress Report this week, characterizing national trends in hepatitis and progress toward national goals for hepatitis prevention and elimination. These reports demonstrate that viral hepatitis remains a significant public health threat, and that further investment in hepatitis prevention and elimination is needed for the U.S. to achieve our national goals for reducing hepatitis infections, deaths, and inequities.

According to the 2022 surveillance report, cases of hepatitis A (HAV) decreased 88% between 2019 to 2022—after widespread outbreaks in 37 states resulted in significant increases between 2015 and 2019. However, the number of cases reported (2,265) was still twice as high as cases in 2015. Notably, most (83%) of cases occurred in urban areas and nearly 1/3 of people diagnosed with hepatitis A reported injection drug use.

Cases of hepatitis B (HBV) were stable between 2021 and 2022, with 2,126 cases reported, equating to an estimated 13,800 new infections of this under-diagnosed disease. Despite this stability, the rate rose 11% among Black people, which was almost double the rate seen among white people. Rates were highest among people aged 40-59, likely reflecting that younger generations are benefiting from routine childhood vaccination that was first recommended in 1991. Rates were highest in states in or near the Appalachian region, with rates highest in West Virginia, Florida, and Maine, and an approximately one-fourth of cases were among people who inject drugs.

In 2022, the rate of hepatitis C (HCV) decreased 6%—after more than a decade of annual increases. However, the incidence of HCV remains significant, with an estimated 67,400 new infections in 2022 (4,854 cases reported). The spread of HCV is characterized by significant inequities, with increases among American Indian/Alaska Native, Black, and Hispanic people, despite the national decrease. More than two-thirds of cases occurred among people aged 20-49, and more than half of cases are associated with injection drug use (where data were available).

Meanwhile, the 2024 Viral Hepatitis National Progress Report revealed that the U.S. only achieved four of ten national targets for hepatitis prevention and elimination in 2024. Targets for reductions in HBV infections and reductions in HCV deaths were met, while targets for reductions in HAV infections, HBV deaths, and HCV infections were not met. To ensure progress on the unmet targets, CDC recommends:

  • Increased testing, vaccination, and treatment
  • Developing and implementing new laboratory diagnostics
  • Leveraging the power of data systems to improve hepatitis surveillance
  • Expanding harm reduction services for people who use drugs

NACCHO applauds these recommendations and emphasizes the important role of local health departments (LHDs) in advancing this work. LHDs play a critical role in hepatitis prevention and elimination, with the majority conducting surveillance and providing or linking to vaccination, testing, treatment, and harm reduction services. However, this work remains significantly underfunded and LHDs need robust and flexible funding to provide hepatitis and harm reduction services, and to advance a syndemic approach to hepatitis, HIV, STIs, and substance use.


Related Posts

Website New Episode w Special Guests
  • Press Release Community Health Harm Reduction Maternal, Child, & Adolescent Health

NACCHO’s Podcast From Washington: Update on H5N1 and...

Update on H5N1 and Local Health Department Pilot Program Addresses Substance...

May 17, 2024

NACCHO’s Podcast From Washington: Update on H5N1 and...

  • Tools & Resources

New Resource- ACEs Questionnaire Use: Cautions and...

NACCHO releases a new resource: ACEs Questionnaire Use: Cautions and...

May 15, 2024 | Camille Adams

New Resource- ACEs Questionnaire Use: Cautions and...

  • HIV, STI, & Viral Hepatitis

New NACCHO Resource: Chlamydia and Gonorrhea...

This toolkit aims to assist community pharmacists across the country with...

May 07, 2024

New NACCHO Resource: Chlamydia and Gonorrhea...

I Stock 000036300232 Medium
  • Chronic Disease Community Health Prevention Research Centers

Webinar Series: Spotlight on Prevention Research Centers

PRC Webinar Spotlight: University of Iowa Prevention Research Center for Rural...

May 03, 2024 | Johanna Segovia

Webinar Series: Spotlight on Prevention Research Centers

  • HIV, STI, & Viral Hepatitis

Request for Proposals: Capacity-Building/Training...

NACCHO is working with the CDC DSTDP to build the capacity of STD public health...

May 01, 2024

Request for Proposals: Capacity-Building/Training...

MDRO Webinar Recording
  • Tools & Resources Webinar Healthcare-Associated Infections ID Featured

Webinar Recording: Multidrug-Resistant Organisms with...

A webinar recording is available for BUILD HAIAR’s March call on preventing and...

Apr 30, 2024 | Candice Young, Irene Halferty

Webinar Recording: Multidrug-Resistant Organisms with...

Website New Episode w Special Guests
  • Press Release Podcast

NACCHO’s Podcast From Washington: New Changes to the WIC...

On this week’s episode: New Changes to WIC Program and Local Health Officer...

Apr 19, 2024

NACCHO’s Podcast From Washington: New Changes to the WIC...

Picture1
  • Community Health Health & Disability

Transformative Health Data Approaches Within the...

CDC is assisting LHDs with technical assistance to improve the quality of data...

Apr 19, 2024 | Jerome Bronson

Transformative Health Data Approaches Within the...

  • Tools & Resources Communications & Public Relations Public Health and Homelessness

NACCHO Social Media Strategy - National Public Health...

National Public Health Week (NPHW) was from April 1 to April 7, 2024.

Apr 11, 2024 | Emma James

NACCHO Social Media Strategy - National Public Health...

Back to Top